20 November 2017 - - Malvern, Pennsylvania-based immunomodulatory technology specialist Realm Therapeutics plc (AIM: RLM) has appointed Sanford (Sandy) Zweifach to its board as a non-executive director, effective December 1, 2017, the company said.
Zweifach has over 25 years of experience in the life sciences industry, with an extensive background in corporate partnering, business development, operations, private and public investing, and capital raising.
He is founder, president and chief executive officer of Nuvelution Pharma, Inc., a company facilitating the clinical advancement of late stage pharmaceutical and biotechnology assets via a Research and Development risk-sharing approach that deploys capital and human resources.
Prior to Nuvelution, Zweifach held executive leadership roles in the biopharmaceutical industry and life sciences investment banking.
He holds a Masters of Science in Human Physiology from the University of California (UC) Davis, a Bachelor of Arts in Biology from UC San Diego, and qualified as a Certified Public Accountant with Coopers and Lybrand.
Matthew Hammond and Daniel Hegglin will retire from the board, effective immediately.
Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel immunomodulatory therapies.
The company has initiated drug development programs, based on its proprietary hypochlorous acid technology at high concentrations, with potential application in a number of therapeutic areas, including dermatology and ophthalmology.